Evidence map›Paper›PMID 42806985›Full record

ArticleFrontiers in immunology2026

Dual blockade of adenosine A

Foteini Patera, Meryem Gultekin, Anna Malecka, Bryony Heath, Tajkia Musarrat, Aanchal Preet Kaur, Poulam M Patel, Stephen J Hill, Andrew M Jackson, Hester A Franks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Foteini PateraCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Meryem GultekinCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Anna MaleckaCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Bryony HeathCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Tajkia MusarratCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Aanchal Preet KaurCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Poulam M PatelCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Stephen J HillUniversity of Nottingham and University of Birmingham Centre of Membrane Proteins and Receptors, The Midlands, United Kingdom.
Andrew M JacksonCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.
Hester A FranksCentre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Science Road, University Park, Nottingham, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenosine accumulation within the tumour microenvironment is a major barrier to effective cancer immunotherapy, driving potent immunosuppression through adenosine receptor signalling. While current clinical strategies primarily target the A

Indexed as

Adenosine-5'-(N-ethylcarboxamide)Adenosine A2 Receptor AntagonistsImmune ToleranceMacrophagesNeoplasmsReceptor, Adenosine A2AReceptor, Adenosine A2BCytokinesHumansImmunotherapySignal TransductionT-LymphocytesTumor MicroenvironmentAdenosine-5'-(N-ethylcarboxamide)Adenosine A2 Receptor AntagonistsADORA2A protein, humanCytokinesReceptor, Adenosine A2AReceptor, Adenosine A2Badenosinecancer immunotherapyhumanmacrophageNECAreceptor

Identifiers

PMID42806985
PMCPMC13616649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.